Fibrosis

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Debiopharm
DebiopharmSwitzerland - Lausanne
1 program
1
EPI-hNE4Phase 21 trial
Active Trials
NCT00455767CompletedEst. Sep 2007
Bristol Myers Squibb
1 program
1
ND-L02-s0201Phase 11 trial
Active Trials
NCT03241264Completed12Est. Oct 2016
Liminal BioSciences
1 program
1
PBI-4050/ PlaceboPhase 11 trial
Active Trials
NCT04695041CompletedEst. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
DebiopharmEPI-hNE4
Liminal BioSciencesPBI-4050/ Placebo
Bristol Myers SquibbND-L02-s0201

Clinical Trials (3)

Total enrollment: 12 patients across 3 trials

Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients

Start: Jul 2006Est. completion: Sep 2007
Phase 2Completed

A Healthy Volunteer Study of PBI-4050

Start: Dec 2020Est. completion: Oct 2021
Phase 1Completed

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

Start: Aug 2016Est. completion: Oct 201612 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space